Nexalis plots capital raise as search goes on for new funding partner by Steve Jones November 3, 2026November 3, 2026 Cannabinoid drug development firm Nexalis Therapeutics is planning a capital raise to relieve the pressure on […]
Nexalis trials still on hold as directors ponder revision of clinical program by Steve Jones August 1, 2026August 5, 2026
Replacement funding falls through as Nexalis studies remain suspended by Adam Sheldon July 6, 2026July 9, 2026
News in brief: Judgment reserved in CDA Clinics QLD legal case; Nexalis completes Phase 1 IRX-616a dosing by Adam Sheldon May 18, 2026June 8, 2026
News in brief: Nexalis advances IRX-616a and IRX-211 programs; Vitura heralds Doctors on Demand growth; Elixinol improves cash flow by Adam Sheldon April 20, 2026June 11, 2026
Financial news in brief: Avecho; InhaleRx; Neurotech; Peak; Zelira; Argent by Adam Sheldon February 2, 2026June 8, 2026
Elixinol records first underlying operating cash flow positive quarter by Adam Sheldon February 2, 2026February 3, 2026
InhaleRx locks in A$1m cap raise and reveals plans to rebrand by Adam Sheldon December 1, 2025February 21, 2026
News in brief: Losses widen for Avecho and Elixinol; InhaleRx secures HREC approval; Zelira cuts deficit; Argent shifts from ‘non-core’ activities by Adam Sheldon August 29, 2025February 21, 2026
